Use of methylphenidate in patients with cancer
Cancer and its treatment are often associated with symptoms such as depression, somnolence, cognitive abnormalities, and fatigue. Methylphenidate, a stimulant medication, is commonly used to treat these symptoms. Several small pilot and a few adequately powered studies have assessed the safety and efficacy of methylphenidate in patients with cancer Overall, the studies so far suggest that methylphenidate is well-tolerated in patients with cancer Further, the studies have provided initial evidence of efficacy of this agent in patients with cancer The present article reviews the evidence base behind the use of methylphenidate in these patients.
Available from: Scott A Irwin
- "With the average time on hospice service being less than 60 days (median less than 21 days) in the United States (National Hospice and Palliative Care Organization, 2007), current standard antidepressant trials oftentimes do not adequately address the needs of hospice patients suffering from depression. Although all of the antidepressants should be on the palliative care psychiatry specialists' list, likely only stimulants should be on the short list (Homsi et al., 2000; Menza et al., 2000; Rozans et al., 2002; Sood et al., 2006), with the thought of getting further psychiatric consultation. Tricyclics and MAO inhibitors should be left to experienced consultants. "
Palliative and Supportive Care 04/2009; 7(1):3-6. DOI:10.1017/S1478951509000029 · 0.98 Impact Factor
Available from: ncbi.nlm.nih.gov
American Journal of Hospice and Palliative Medicine 23(4):267; author reply 267-8. DOI:10.1177/1049909106290381 · 1.38 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.